{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:10:25Z","timestamp":1790514625669,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004963","name":"Seventh Framework Programme","doi-asserted-by":"publisher","award":["279227"],"award-info":[{"award-number":["279227"]}],"id":[{"id":"10.13039\/501100004963","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12888-016-1167-0","type":"journal-article","created":{"date-parts":[[2016,12,12]],"date-time":"2016-12-12T08:15:51Z","timestamp":1481530551000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in Iceland"],"prefix":"10.1186","volume":"16","author":[{"given":"Oddur","family":"Ingimarsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"MacCabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magn\u00fas","family":"Haraldsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halld\u00f3ra","family":"J\u00f3nsd\u00f3ttir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Engilbert","family":"Sigurdsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,12,12]]},"reference":[{"issue":"2 Suppl","key":"1167_CR1","first-page":"1","volume":"161","author":"AF Lehman","year":"2004","unstructured":"Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2 Suppl):1\u201356.","journal-title":"Am J Psychiatry"},{"issue":"1\u20132","key":"1167_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.psychres.2012.02.013","volume":"197","author":"T Suzuki","year":"2012","unstructured":"Suzuki T, Remington G, Mulsant BH, Uchida H, Rajji TK, Graff-Guerrero A, et al. Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation. Psychiatry Res. 2012;197(1\u20132):1\u20136.","journal-title":"Psychiatry Res"},{"key":"1167_CR3","doi-asserted-by":"crossref","unstructured":"Stroup TS, Gerhard T, Crystal S, Huang C, Olfson M. Comparative Effectiveness of Clozapine and Standard Antipsychotic Treatment in Adults With Schizophrenia. Am J Psychiatry. 2015;173(2):166\u201373.","DOI":"10.1176\/appi.ajp.2015.15030332"},{"issue":"1","key":"1167_CR4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1093\/bmb\/ldv017","volume":"114","author":"J Lally","year":"2015","unstructured":"Lally J, MacCabe JH. Antipsychotic medication in schizophrenia: a review. Br Med Bull. 2015;114(1):169\u201379.","journal-title":"Br Med Bull"},{"issue":"6","key":"1167_CR5","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3109\/08039488.2016.1155234","volume":"70","author":"O Ingimarsson","year":"2016","unstructured":"Ingimarsson O, MacCabe JH, Haraldsson M, J\u00f3nsd\u00f3ttir H, Sigurdsson E. Clozapine treatment and discontinuation in Iceland: a national longitudinal study using electronic patient records. Nord J Psychiatry. 2016;70(6):450\u20135.","journal-title":"Nord J Psychiatry"},{"issue":"9","key":"1167_CR6","doi-asserted-by":"publisher","first-page":"915","DOI":"10.2217\/pgs.15.67","volume":"16","author":"M Verbelen","year":"2015","unstructured":"Verbelen M, Lewis CM. How close are we to a pharmacogenomic test for clozapine-induced agranulocytosis? Pharmacogenomics. 2015;16(9):915\u20137.","journal-title":"Pharmacogenomics"},{"issue":"15","key":"1167_CR7","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.2217\/pgs.13.182","volume":"14","author":"BW Spencer","year":"2013","unstructured":"Spencer BW, Prainsack B, Rujescu D, Giegling I, Collier DA, Gaughran F, et al. Opening Pandora\u2019s box in the UK: a hypothetical pharmacogenetic test for clozapine. Pharmacogenomics. 2013;14(15):1907\u201314.","journal-title":"Pharmacogenomics"},{"issue":"2","key":"1167_CR8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s40263-016-0311-1","volume":"30","author":"J Nielsen","year":"2016","unstructured":"Nielsen J, Young C, Ifteni P, Kishimoto T, Xiang YT, Schulte PF, et al. Worldwide differences in regulations of clozapine use. CNS Drugs. 2016;30(2):149\u201361.","journal-title":"CNS Drugs"},{"issue":"5","key":"1167_CR9","first-page":"131","volume":"6","author":"M Dixon","year":"2014","unstructured":"Dixon M, Dada C. How clozapine patients can be monitored safely and effectively. Clin Pharm. 2014;6(5):131\u20132.","journal-title":"Clin Pharm"},{"issue":"4","key":"1167_CR10","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1345\/aph.1G396","volume":"40","author":"P Schulte","year":"2006","unstructured":"Schulte P. Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring. Ann Pharmacother. 2006;40(4):683\u20138.","journal-title":"Ann Pharmacother"},{"key":"1167_CR11","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1192\/bjp.175.6.576","volume":"175","author":"J Munro","year":"1999","unstructured":"Munro J, O\u2019Sullivan D, Andrews C, Arana A, Mortimer A, Kerwin R. Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br J Psychiatry. 1999;175:576\u201380.","journal-title":"Br J Psychiatry"},{"issue":"3","key":"1167_CR12","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1056\/NEJM199307153290303","volume":"329","author":"JM Alvir","year":"1993","unstructured":"Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med. 1993;329(3):162\u20137.","journal-title":"N Engl J Med"},{"issue":"6","key":"1167_CR13","doi-asserted-by":"publisher","first-page":"837","DOI":"10.4088\/JCP.11m07244","volume":"73","author":"L Lahdelma","year":"2012","unstructured":"Lahdelma L, Appelberg B. Clozapine-induced agranulocytosis in Finland, 1982\u20132007: long-term monitoring of patients is still warranted. J Clin Psychiatry. 2012;73(6):837\u201342.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 3","key":"1167_CR14","first-page":"3","volume":"59","author":"G Honigfeld","year":"1998","unstructured":"Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J. Reducing clozapine-related morbidity and mortality: 5\u00a0years of experience with the Clozaril National Registry. J Clin Psychiatry. 1998;59 Suppl 3:3\u20137.","journal-title":"J Clin Psychiatry"},{"key":"1167_CR15","unstructured":"Leponex SPC in Iceland: Icelandic Medicines Agency; 2014. http:\/\/serlyfjaskra.is\/FileRepos\/0a2049a2-618f-e511-80cf-001e4f17a1f7\/Leponex-SmPC.pdf . Accessed 12 April 2016."},{"issue":"3","key":"1167_CR16","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1093\/schbul\/sbu120","volume":"41","author":"RD Hayes","year":"2014","unstructured":"Hayes RD, Downs J, Chang CK, Jackson RG, Shetty H, Broadbent M, et al. The effect of clozapine on premature mortality: an assessment of clinical monitoring and other potential confounders. Schizophr Bull. 2014;41(3):644\u201355.","journal-title":"Schizophr Bull"},{"issue":"959","key":"1167_CR17","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1136\/pgmj.2004.031161","volume":"81","author":"S Rajagopal","year":"2005","unstructured":"Rajagopal S. Clozapine, agranulocytosis, and benign ethnic neutropenia. Postgrad Med J. 2005;81(959):545\u20136.","journal-title":"Postgrad Med J"},{"key":"1167_CR18","unstructured":"FDA. What\u2019s New with Clozapine: An Overview: FDA; 2015. https:\/\/www.clozapinerems.com\/CpmgClozapineUI\/home.u# #. Accessed 10 Dec 2016."},{"issue":"7","key":"1167_CR19","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1001\/archpsyc.1978.01770310043002","volume":"35","author":"J Endicott","year":"1978","unstructured":"Endicott J, Spitzer RL. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry. 1978;35(7):837\u201344.","journal-title":"Arch Gen Psychiatry"},{"key":"1167_CR20","unstructured":"Clozapine monitoring guidelines: Teva; 2014. http:\/\/www.tevaclozapine.com\/documents\/Clozapine_Monitoring_Guidelines.pdf . Accessed 12 Apr 2016."},{"issue":"2","key":"1167_CR21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1055\/s-0030-1249071","volume":"43","author":"MA Rettenbacher","year":"2010","unstructured":"Rettenbacher MA, Hofer A, Kemmler G, Fleischhacker WW. Neutropenia induced by second generation antipsychotics: a prospective investigation. Pharmacopsychiatry. 2010;43(2):41\u20134.","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"1167_CR22","first-page":"287","volume":"28","author":"M Hummer","year":"1992","unstructured":"Hummer M, Kurz M, Barnas C, Fleischhacker WW. Transient neutropenia induced by clozapine. Psychopharmacol Bull. 1992;28(3):287\u201390.","journal-title":"Psychopharmacol Bull"},{"issue":"4","key":"1167_CR23","first-page":"683","volume":"32","author":"SM Essock","year":"1996","unstructured":"Essock SM, Hargreaves WA, Covell NH, Goethe J. Clozapine\u2019s effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacol Bull. 1996;32(4):683\u201397.","journal-title":"Psychopharmacol Bull"},{"issue":"1","key":"1167_CR24","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/acps.12233","volume":"130","author":"MC Davis","year":"2014","unstructured":"Davis MC, Fuller MA, Strauss ME, Konicki PE, Jaskiw GE. Discontinuation of clozapine: a 15-year naturalistic retrospective study of 320 patients. Acta Psychiatr Scand. 2014;130(1):30\u20139.","journal-title":"Acta Psychiatr Scand"},{"key":"1167_CR25","unstructured":"Global status report on road safety: WHO; 2015. http:\/\/www.who.int\/violence_injury_prevention\/road_safety_status\/2015\/en\/ . Accessed 3 Apr 2016."},{"issue":"11","key":"1167_CR26","doi-asserted-by":"publisher","first-page":"e1410","DOI":"10.4088\/JCP.14m09326","volume":"76","author":"N Meyer","year":"2015","unstructured":"Meyer N, Gee S, Whiskey E, Taylor D, Mijovic A, Gaughran F, et al. Optimizing outcomes in clozapine rechallenge following neutropenia: a cohort analysis. J Clin Psychiatry. 2015;76(11):e1410\u20136.","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"1167_CR27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/acps.12327","volume":"130","author":"K Beck","year":"2014","unstructured":"Beck K, McCutcheon R, Bloomfield MA, Gaughran F, Reis Marques T, MacCabe J, et al. The practical management of refractory schizophrenia--the maudsley treatment REview and assessment team service approach. Acta Psychiatr Scand. 2014;130(6):427\u201338.","journal-title":"Acta Psychiatr Scand"},{"issue":"10","key":"1167_CR28","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.4088\/JCP.11r06977","volume":"73","author":"D Cohen","year":"2012","unstructured":"Cohen D, Bogers JP, van Dijk D, Bakker B, Schulte PF. Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy. J Clin Psychiatry. 2012;73(10):1307\u201312.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"1167_CR29","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2217\/fnl.14.23","volume":"9","author":"B Nair","year":"2014","unstructured":"Nair B, MacCabe JH. Making clozapine safer: current perspectives on improving its tolerability. Future Neurol. 2014;9(3):313\u201322.","journal-title":"Future Neurol"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-016-1167-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12888-016-1167-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-016-1167-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T01:44:23Z","timestamp":1498355063000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-016-1167-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1167"],"URL":"https:\/\/doi.org\/10.1186\/s12888-016-1167-0","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12]]},"article-number":"441"}}